Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 1969-1976

  Raitila, Anniina ^a   Lehtonen, Heli J ^a   Arola, Johanna ^b   Heliövaara, Elina ^a   Ahlsten, Manuel ^a   Georgitsi, Marianthi ^a   Jalanko, Anu ^c   Paetau, Anders ^b   Aaltonen, Lauri A ^a   Karhu, Auli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; GENE PRODUCT; GROWTH HORMONE; HYPOXIA INDUCIBLE FACTOR 1BETA; KI 67 ANTIGEN; PROTEIN ARNT2; UNCLASSIFIED DRUG;

AIP GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE INACTIVATION; GENE MUTATION; GENETIC PREDISPOSITION; GROWTH HORMONE RELEASE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MODEL;

EID: 77957333250     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100138     Document Type: Article

References (38)

1. Heaney AP, Melmed S: Molecular targets in pituitary tumours. Nat Rev Cancer 2004, 4:285-295
2. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA: Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230
3. Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O, Lubinski J, Launonen V, Vahteristo P, Aaltonen LA: Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA 2007, 104:4101-4105
4. Tichomirowa MA, Daly AF, Beckers A: Familial pituitary adenomas. J Intern Med 2009, 266:5-18
5. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A,Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M: The role of the Aip gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93:2390-2401
6. Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, Launonen V, Aaltonen LA: Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007, 96:352-356
7. Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Makinen MJ, Birkenkamp- Demtroder K, Salmenkivi K, Orntoft TF, Arola J, Launonen V, Vahteristo P, Aaltonen LA: No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 2007, 14:901-906
8. Raitila A, Georgitsi M, Bonora E, Vargiolu M, Tuppurainen K, Makinen MJ, Vierimaa O, Salmela PI, Launonen V, Vahteristo P, Aaltonen LA, Romeo G, Karhu A: Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest 2009, 32:426-429
9. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio- Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92:1891-1896
10. Heliövaara E, Raitila A, Launonen V, Paetau A, Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P, Tuppurainen K, Makinen M, Aaltonen LA, Karhu A: The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am J Pathol 2009, 175:2501-2507
11. Petrulis JR, Perdew GH: The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 2002, 141:25-40
12. Rankin EB, Giaccia AJ: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008, 15:678-685
13. Matthews J, Gustafsson JA: Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 2006, 4:e016
14. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I: The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA 2003, 100:6517-6522
15. Dougherty EJ, Pollenz RS: Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. Toxicol Sci 2008, 103:191-206
16. Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, Saijo Y, Gotoh O, Sogawa K, Fujii-Kuriyama Y: cDNA cloning and tissuespecific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996, 16:1706-1713
17. Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA: Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J Biol Chem 2007, 282:35924-35932
18. Lin BC, Nguyen LP, Walisser JA, Bradfield CA: A hypomorphic allele of aryl hydrocarbon receptor-associated protein-9 produces a phenocopy of the AHR-null mouse. Mol Pharmacol 2008, 74:1367-1371
19. Stanford WL, Cohn JB, Cordes SP: Gene-trap mutagenesis: past, present and beyond. Nat Rev Genet 2001, 2:756-768
20. Lee H, Douglas-Jones AG, Morgan JM, Jasani B: The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinoma. J Clin Pathol 2002, 55:236-238
21. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A: Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996, 56:3331-3337
22. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, Lavergne K, Villeneuve A, Gaudin T, Brandstrom H, Beck A, Verner A, Kingsley J, Harmsen E, Labuda D, Morgan K, Vohl MC, Naumova AK, Sinnett D, Hudson TJ: A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics 2004, 16:184-193
23. Seuntjens E, Hauspie A, Roudbaraki M, Vankelecom H, Denef C: Combined expression of different hormone genes in single cells of normal rat and mouse pituitary. Arch Physiol Biochem 2002, 110:12-15
24. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720
25. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS: A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001, 98:1118-1123
26. Yin Z, Williams-Simons L, Parlow AF, Asa S, Kirschner LS: Pituitaryspecific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol 2008, 22:380-387
27. Clemmons DR, Dehoff M, McCusker R, Elgin R, Busby W: The role of insulin-like growth factor I in the regulation of growth. J Anim Sci 1987, 65:168-179
28. Strachan T, Read AP: Creating Disease Models using Gene Transfer. Human Molecular Genetics 3. Edited by Strachan T, Read AP. New York, Garland Science, 2004, pp. 575-605
29. Knosp E, Kitz K, Perneczky A: Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989, 25:927-930
30. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G: Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 1999, 52:107-111
31. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 2002, 9:103-113
32. Pereira-Lima JF, Marroni CP, Pizarro CB, Barbosa-Coutinho LM, Ferreira NP, Oliveira MC: Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication. Neuroendocrinology 2004, 79:119-124
33. Nakao H, Koga M, Arao M, Nakao M, Sato B, Kishimoto S, Saitoh Y, Arita N, Mori S: Enzyme-immunoassay for estrogen receptors in human pituitary adenomas. Acta Endocrinol 1989, 120:233-238
34. Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL: Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 1995, 80:3621-3627
35. Yoshida D, Kim K, Yamazaki M, Teramoto A: Expression of hypoxiainducible factor 1alpha and cathepsin D in pituitary adenomas. Endocr Pathol 2005, 16:123-131
36. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47
37. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91
38. Maltepe E, Keith B, Arsham AM, Brorson JR, Simon MC: The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem Biophys Res Commun 2000, 273:231-238